NASDAQ: CADL
Candel Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CADL

Based on 4 analysts offering 12 month price targets for Candel Therapeutics Inc

Min Forecast
$14.00+125.81%
Avg Forecast
$20.00+222.58%
Max Forecast
$26.00+319.35%

Should I buy or sell CADL stock?

Based on 4 analysts offering ratings for Candel Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CADL's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CADL as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their CADL stock forecasts and price targets.

CADL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-18Find Out Why
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2025-12-08
lockedlocked$00.00+00.00%2025-11-21

1 of 1

Forecast return on equity

Is CADL forecast to generate an efficient return?

Company
N/A
Industry
66.81%
Market
174.65%

Forecast return on assets

Is CADL forecast to generate an efficient return on assets?

Company
N/A
Industry
30.43%

CADL earnings per share forecast

What is CADL's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$1.32
Avg 2 year Forecast
-$0.76
Avg 3 year Forecast
$0.81

CADL revenue forecast

What is CADL's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$57.6M
Avg 3 year Forecast
$252.9M

CADL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CADL$6.20$20.00+222.58%Strong Buy
IMMX$8.60$19.20+123.26%Buy
LYEL$21.49$41.00+90.79%Buy
LRMR$4.40$13.50+206.82%Strong Buy
RGNX$8.69$27.57+217.27%Strong Buy

Candel Therapeutics Stock Forecast FAQ

Is Candel Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: CADL) stock is to Strong Buy CADL stock.

Out of 4 analysts, 4 (100%) are recommending CADL as a Strong Buy, 0 (0%) are recommending CADL as a Buy, 0 (0%) are recommending CADL as a Hold, 0 (0%) are recommending CADL as a Sell, and 0 (0%) are recommending CADL as a Strong Sell.

If you're new to stock investing, here's how to buy Candel Therapeutics stock.

What is CADL's earnings growth forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.62%.

Candel Therapeutics's earnings in 2026 is -$38,182,000.On average, 8 Wall Street analysts forecast CADL's earnings for 2026 to be -$96,729,892, with the lowest CADL earnings forecast at -$165,098,573, and the highest CADL earnings forecast at -$59,220,140. On average, 8 Wall Street analysts forecast CADL's earnings for 2027 to be -$55,301,430, with the lowest CADL earnings forecast at -$95,470,045, and the highest CADL earnings forecast at $24,610,967.

In 2028, CADL is forecast to generate $59,527,778 in earnings, with the lowest earnings forecast at -$61,732,510 and the highest earnings forecast at $204,578,667.

What is CADL's revenue growth forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.21%.

Candel Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast CADL's revenue for 2026 to be $0, with the lowest CADL revenue forecast at $0, and the highest CADL revenue forecast at $0. On average, 9 Wall Street analysts forecast CADL's revenue for 2027 to be $4,216,605,847, with the lowest CADL revenue forecast at $603,847,666, and the highest CADL revenue forecast at $10,175,463,099.

In 2028, CADL is forecast to generate $18,527,077,715 in revenue, with the lowest revenue forecast at $7,315,976,316 and the highest revenue forecast at $28,126,087,499.

What is CADL's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CADL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 30.43%.

What is CADL's Price Target?

According to 4 Wall Street analysts that have issued a 1 year CADL price target, the average CADL price target is $20.00, with the highest CADL stock price forecast at $26.00 and the lowest CADL stock price forecast at $14.00.

On average, Wall Street analysts predict that Candel Therapeutics's share price could reach $20.00 by Mar 18, 2027. The average Candel Therapeutics stock price prediction forecasts a potential upside of 222.58% from the current CADL share price of $6.20.

What is CADL's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CADL) Candel Therapeutics's current Earnings Per Share (EPS) is -$0.72. On average, analysts forecast that CADL's EPS will be -$1.32 for 2026, with the lowest EPS forecast at -$2.25, and the highest EPS forecast at -$0.81. On average, analysts forecast that CADL's EPS will be -$0.76 for 2027, with the lowest EPS forecast at -$1.30, and the highest EPS forecast at $0.34. In 2028, CADL's EPS is forecast to hit $0.81 (min: -$0.84, max: $2.79).

What is CADL's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CADL) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.